National Cancer Institute (NCI): Neoplasms, Plasma Cell trials
The registry lists 13 Neoplasms, Plasma Cell studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 3Phase 2 5Phase 3 1No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Phase II Trial of Anti-KIR in Smoldering Multiple MyelomaTerminatedNCT01248455Phase 2Results posted
- Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
- Testing a Spanish Version of a Patient Toxicity QuestionnaireCompletedNCT01517152
- Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)TerminatedNCT01109407
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Genome Expression in Lymphoma, Leukemia and Multiple MyelomaCompletedNCT00339963
- Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
- Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00033332Phase 3
- Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00019097Phase 2
- Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00003853Phase 2
- Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
- Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and CancerCompletedNCT00001582